What should we know about metabolic syndrome and lipodystrophy in AIDS?;O que devemos saber sobre síndrome metabólica e lipodistrofia na AIDS?

Revista da Associacao Medica Brasileira

Volumn 58, Issue 1, 2012, Pages 70-75

  Signorini, Dario Jose Hart Pontes ^a   Monteiro, Michelle Carreira Miranda ^b   de Andrade, Marion de Fátima Castro ^c   Signorini, Dario Hart ^d   Eyer Silva, Walter de Araújo ^a  

^a FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^b HOSPITAL UNIVERSITÁRIO GAFFRÉE E GUINLE   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d ESTÁCIO DE SÁ UNIVERSITY   (Brazil)

Author keywords

Antiretroviral therapy; Cross sectional studies; Highly active; HIV; HIV associated lipodystrophy syndrome; Metabolic syndrome X; Risk factors

Indexed keywords

EID: 84858057801     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-42302012000100017     Document Type: Article

References (25)

1. Diehl LA, Dias JR, Paes AC, Thomazini MC, Garcia LR, Cinagawa E, et al. Prevalência da lipodistrofia associada ao HIV em pacientes ambulatoriais brasileiros: relação com síndrome metabólica e fatores de risco cardiovascular. Arq Bras Endocrinol Metabol. 2008;52(4):658-67.
2. Signorini DJHP, Codeço CT, Carvalho MS, Campos DP, Monteiro MCM, Andrade MFC, et al. Effect of sociodemographic, clinical-prophylactic and therapeutic procedures on survival of AIDS patients assisted in a Brazilian outpatient clinic. Rev Bras Epidemiol. 2005;8(3):253-61 Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-790X2005000300007.
3. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev. 2008;29(7):777-822.
4. Mangili A, Jacobson DL, Gerrior J, Polak JF, Gorbach SL, Wanke CA. Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV. Clin Infect Dis. 2007;44(10):1368-74.
5. Organization WH. Stop the Global Epidemic of Chronic Disease. 2011 [cited 2011 feb 17]. Available from: https://apps.who.int/infobase/report.aspx.
6. Organization WH. Global strategy on diet, physical activity and health. 2011 [cited 2011 feb 17]. Available from: http://www.who.int/dietphysicalactivity/en/.
7. Santos CP, Felipe YX, Braga PE, Ramos D, Lima RO, Segurado AC. Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. Aids. 2005;19(Suppl 4):S14-21.
8. Gelenske T, Bandeira EFFA, Alencar Ximenes RA, Lacerda de Melo HR, Militão de Albuquerque MD, Carvalho EH, et al. Risk factors in human immunodeficiency virus/acquired immunodeficiency syndrome patients undergoing antiretroviral therapy in the State of Pernambuco, Brazil: a case-control study. Metab Syndr Relat Disord. 2010;8(3):271-7.
9. Villarroya F, Domingo P, Giralt M. Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment. Biochim Biophys Acta. 2010;1801(3):392-9.
10. Godoy-Matos AF. Endocardiometabologia na prática clínica. São Paulo: Guanabara Koogan; 2011.
11. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr., et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. Aids. 2001;15(11):1389-98.
12. Sociedade Brasileira de Hipertensão, Sociedade Brasileira de Endocrinologia e Metabologia, et al. I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica. Arq Bras Cardiol. 2005;84(Supl 1):3-28.
13. Team RDC. R: a language and environment for statistical computing. 2.9. Vienna, Austria: R Foundation for Statistical Computing; 2009.
14. Cahn P, Leite O, Rosales A, Cabello R, Alvarez CA, Seas C, et al. Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART. Braz J Infect Dis. 2010;14(2):158-66.
15. Bonfanti P, Giannattasio C, Ricci E, Facchetti R, Rosella E, Franzetti M, et al. HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr. 2007;45(4):426-31.
16. Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis. 2007;44(5):726-34.
17. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. Aids. 1999;13(18):2493-505.
18. Johnsen S, Dolan SE, Fitch KV, Kanter JR, Hemphill LC, Connelly JM, et al. Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab. 2006;91(12):4916-24.
19. Estrada V, Martinez-Larrad MT, Gonzalez-Sanchez JL, Villar NG, Zabena C, Fernandez C, et al. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism. 2006;55(7):940-5.
20. Alvarez C, Salazar R, Galindez J, Rangel F, Castaaeda ML, Lopardo G, et al. Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America. Braz J Infect Dis. 2010;14(3):256-63.
21. Salaroli LB, Barbosa GC, Mill JG, Molina MC. Prevalência de síndrome metabólica em estudo de base populacional, Vitória, ES-Brazil. Arq Bras Endocrinol Metabol. 2007;51(7):1143-52.
22. Silva EF, Bassichetto KC, Lewi DS. Lipid profile, cardiovascular risk factors and metabolic syndrome in a group of AIDS patients. Arq Bras Cardiol. 2009;93(2):113-8.
23. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361(9359):726-35.
24. Jerico C, Knobel H, Montero M, Ordonez-Llanos J, Guelar A, Gimeno JL, et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care. 2005;28(1):132-7.
25. Signorini DJ, Monteiro MC, Signorini DH, Eyer-Silva WA. Prevalence and determinant factors to lipid abnormalities among HIV-infected patients: a cross-sectional study of 812 patients. Arq Bras Endocrinol Metabol. 2010;54(6):583.